Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.
In a press release late yesterday, Coherus announced it has entered into an agreement with Pharmakon Advisors to revise the terms of its loan agreement entered in January 2022. After Coherus closes the previously announced divestiture of its noncore ophthalmology business to Sandoz Group, it plans to prepay $175 million of its $250 million principal balance under its loan in the second quarter of 2024. That will leave a balance of $75 million remaining on the loan and reduce Coherus' projected annual interest payments by around 70%.
The news shouldn't be entirely surprising; when Coherus announced the divestiture two weeks ago -- which included a $170 million up-front cash payment from Sandoz plus an additional amount (to be determined at closing) for working capital adjustments and Cimerli product inventory -- CEO Denny Lanfear told investors the company would use the proceeds "to pay down debt, reduce interest costs, and take the opportunity to focus on our core therapeutic area, oncology."
Source Fool.com
Coherus Bioscien. Stock
Based on 2 Buy predictions and 2 Sell predictions the sentiment towards Coherus Bioscien. is rather balanced.
As a result the target price of 3 € shows a positive potential of 42.52% compared to the current price of 2.11 € for Coherus Bioscien..
